Search results
Results from the WOW.Com Content Network
Permission is granted to copy, distribute and/or modify this document under the terms of the GNU Free Documentation License, Version 1.2 or any later version published by the Free Software Foundation; with no Invariant Sections, no Front-Cover Texts, and no Back-Cover Texts.
On mammography, ILC shows spiculated mass with ill-defined margins that has similar or lower density than surrounding breast tissues. This happens only at 44–65% of the time. Architectural distortion on surrounding breast tissues is only seen in 10–34% of the cases. It can be reported as benign in 8–16% of the mammography cases. [10]
Histopathologic types of breast cancer, with relative incidences and prognoses. "Lobular carcinoma in situ" is at right. LCIS is identified in 0.5% to 1.5% of benign breast biopsies. These biopsies are often done in response to suspicious mammographic findings, as discussed in the Diagnosis section of this article.
Worldwide, breast cancer is the leading type of cancer in women, accounting for 25% of all cases. [5] It is most common in women over age 50. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. [6]
MCF-7 Cells. MCF-7 is a breast cancer cell line isolated in 1970 from a 69-year-old White woman. [1] MCF-7 is the acronym of Michigan Cancer Foundation-7, referring to the institute in Detroit where the cell line was established in 1973 by Herbert Soule and co-workers. [2]
This is an accepted version of this page This is the latest accepted revision, reviewed on 14 January 2025. Cancer that originates in mammary glands Medical condition Breast cancer An illustration of breast cancer Specialty Surgical Oncology Symptoms A lump in a breast, a change in breast shape, dimpling of the skin, fluid from the nipple, a newly inverted nipple, a red scaly patch of skin on ...
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
The basal-like carcinoma is a recently proposed subtype of breast cancer defined by its gene expression and protein expression profile. [1]Breast cancer can be divided into five molecular subtypes, including luminal subtype A, luminal subtype B, normal breast-like subtype, HER-2 overexpression subtype, and basal-like subtype. [2]